Aditx Therapeutics, Inc. (ADTX)
Market Cap | 37.24M |
Revenue (ttm) | n/a |
Net Income (ttm) | -9.15M |
Shares Out | 14.49M |
EPS (ttm) | -1.33 |
PE Ratio | n/a |
Forward PE | 5.91 |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | April 19 |
Last Price | $2.59 |
Previous Close | $2.60 |
Change ($) | -0.02 |
Change (%) | -0.58% |
Day's Open | 2.64 |
Day's Range | 2.49 - 2.67 |
Day's Volume | 429,709 |
52-Week Range | 1.62 - 9.58 |
MOUNTAIN VIEW, Calif., April 13, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system,...
MOUNTAIN VIEW, Calif., April 6, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, ...
MOUNTAIN VIEW, Calif., April 1, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, ...
Aditx Therapeutics Inc (NASDAQ: ADTX) is preparing its therapeutic program for psoriasis for First-In-Human clinical trials by the end of this year. The trials, which are planned to begin in Q4 2021, wi...
MOUNTAIN VIEW, Calif., March 24, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system,...
Mountain View, CA, March 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company focused on improving the health o...
Dr. Tyan Will Lead and Advance Organ Transplantation Therapeutic Program
Balance Sheet Further Strengthened by Receipt of Additional $3.3 Million from Exercise of Existing Warrants
Shares of ADiTx Therapeutics Inc (NASDAQ: ADTX) are trading at a five-month high Thursday after ADiTx announced it would launch the AditxtScore Immune Monitoring Platform on Feb. 1. The initial applicat...
About ADTX
ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products ... [Read more...]
Industry Biotechnology | IPO Date Jun 30, 2020 |
Stock Exchange NASDAQ | Ticker Symbol ADTX |